Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel

Hypertension Research

Volumn 35, Issue 1, 2012, Pages 77-81

  Shimizu, Hideo ^a   Nakagami, Hironori ^b   Yasumasa, Natsuki ^b   Mariana, Osako Kiomy ^a   Kyutoku, Mariko ^a   Koriyama, Hiroshi ^a   Nakagami, Futoshi ^a   Shimamura, Munehisa ^b   Rakugi, Hiromi ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

blocker; bone mineral density; calcium channel blocker; osteoclast; osteoporosis

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMLODIPINE; CALCIUM; CARVEDILOL; CILNIDIPINE; DEOXYPYRIDINOLINE; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BONE DENSITY; BONE METABOLISM; CELL COUNT; COLLAGEN DEGRADATION; CONTROLLED STUDY; FEMALE; HEART RATE; HYPERTENSION; NONHUMAN; NORADRENALIN RELEASE; OSTEOCLAST; OSTEOPOROSIS; OVARIECTOMY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC NERVE; TIBIA;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BONE AND BONES; BONE DENSITY; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; DIHYDROPYRIDINES; FEMALE; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, INBRED SHR;

EID: 84855453838     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.143     Document Type: Article

References (40)

1. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: A prospective study. Study of osteoporotic fractures research group. Lancet 1999; 354: 971-975. (Pubitemid 29438401)
2. Tsuda K, Nishio I, Masuyama Y. Bone mineral density in women with essential hypertension. Am J Hypertens 2001; 14: 704-707. (Pubitemid 32612537)
3. Imaoka M, Morimoto S, Kitano S, Fukuo F, Ogihara T. Calcium metabolism in elderly hypertensive patients: Possible participation of exaggerated sodium, calcium and phosphate excretion. Clin Exp Pharmacol Physiol 1991; 18: 631-641.
4. McCarron DA, Pingree PA, Rubin RJ, Gaucher SM, Molitch M, Krutzik S. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension 1980; 2: 162-168. (Pubitemid 10010498)
5. Perez-Castrillon JL, Justo I, Silva J, Sanz A, Igea R, Escudero P, Pueyo C, Diaz C, Hernandez G, Duenas A. Bone mass and bone modelling markers in hypertensive postmenopausal women. J Hum Hypertens 2003; 17: 107-110. (Pubitemid 36292365)
6. Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: A randomized controlled trial. Am J Med 2000; 109: 362-370.
7. Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T, Pols HA, Stricker BH. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139: 476-482.
8. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004; 292: 1326-1332.
9. Wasnich R, Davis J, Ross P, Vogel J. Effect of thiazide on rates of bone mineral loss: A longitudinal study. BMJ 1990; 301: 1303-1305.
10. Rejnmark L, Vestergaard P, Mosekilde L. Reduced fracture risk in users of thiazide diuretics. Calcif Tissue Int 2005; 76: 167-175. (Pubitemid 41557145)
11. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ace inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006; 24: 581-589. (Pubitemid 43261923)
12. Albers MM, Johnson W, Vivian V, Jackson RD. Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone 1991; 12: 39-42.
13. Zacharieva S, Shigarminova R, Nachev E, Kamenov Z, Atanassova I, Orbetzova M, Stoynev A, Doncheva N, Borissova AM. Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause. Methods Find Exp Clin Pharmacol 2003; 25: 209-213. (Pubitemid 36604239)
14. Boesgaard S, Hyldstrup L, Feldstedt M. Changes in calcium homoeostasis and bone formation in patients recovering from acute myocardial infarction: Effect of verapamil treatment. Danish study group on verapamil in myocardial infarction. Eur J Clin Pharmacol 1991; 41: 521-523.
15. Guggino SE, Lajeunesse D, Wagner JA, Snyder SH. Bone remodeling signaled by a dihydropyridine-and phenylalkylamine-sensitive calcium channel. Proc Natl Acad Sci USA 1989; 86: 2957-2960. (Pubitemid 19112656)
16. Hirning LD, Fox AP, McCleskey EW, Olivera BM, Thayer SA, Miller RJ, Tsien RW. Dominant role of n-type ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 1988; 239: 57-61. (Pubitemid 18029496)
17. Takahara A, Fujita S, Moki K, Ono Y, Koganei H, Iwayama S, Yamamoto H. Neuronal ca2+ channel blocking action of an antihypertensive drug, cilnidipine, in imr-32 human neuroblastoma cells. Hypertens Res 2003; 26: 743-747. (Pubitemid 37258663)
18. Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
19. Takahara A. Cilnidipine: A new generation ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009; 27: 124-139.
20. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 305-317. (Pubitemid 35345151)
21. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC. Betaadrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 2004; 19: 19-24. (Pubitemid 41295133)
22. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008; 22: 2465-2475. (Pubitemid 351948664)
23. Shimizu H, Nakagami H, Tsukamoto I, Morita S, Kunugiza Y, Tomita T, Yoshikawa H, Kaneda Y, Ogihara T, Morishita R. Nfkappab decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Ther 2006; 13: 933-941. (Pubitemid 43827335)
24. Nuzzo A, Rossi R, Modena MG. Hypertension alone or related to the metabolic syndrome in postmenopausal women. Expert Rev Cardiovasc Ther 2010; 8: 1541-1548.
25. Resnick LM, Laragh JH, Sealey JE, Alderman MH. Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 1983; 309: 888-891. (Pubitemid 13014029)
26. Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. J Nephrol 2000; 13: 169-177. (Pubitemid 30449492)
27. Varagic J, Susic D, Frohlich ED. Cilnidipine improves spontaneously hypertensive rat coronary hemodynamics without altering cardiovascular mass and collagen. J Hypertens 2002; 20: 317-322. (Pubitemid 34913798)
28. Sakata K, Yoshida H, Tamekiyo H, Obayashi K, Nawada R, Doi O, Mori N. Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension. Drugs Exp Clin Res 2003; 29: 117-123. (Pubitemid 37498413)
29. Nagai H, Minatoguchi S, Chen XH, Wang N, Arai M, Uno Y, Lu C, Misao Y, Onogi H, Kobayashi H, Takemura G, Maruyama R, Fujiwara T, Fujiwara H. Cilnidipine, an n+ltype dihydropyridine ca channel blocker, suppresses the occurrence of ischemia/reperfusion arrhythmia in a rabbit model of myocardial infarction. Hypertens Res 2005; 28: 361-368. (Pubitemid 40895059)
30. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-1549. (Pubitemid 350199443)
31. Zhou X, Ono H, Ono Y, Frohlich ED. N-and l-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-name/shr model. J Hypertens 2002; 20: 993-1000. (Pubitemid 34913681)
32. Toba H, Yoshida M, Tojo C, Nakano A, Oshima Y, Kojima Y, Noda K, Wang J, Kobara M, Nakata T. L/n-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetatesalt hypertensive rats. Hypertens Res 2011; 34: 521-529.
33. Aritomi S, Niinuma K, Ogawa T, Konda T, Nitta K. Effects of an n-type calcium antagonist on angiotensin ii-renin feedback. Am J Nephrol 2011; 33: 168-175.
34. Shimizu H, Nakagami H, Osako MK, Nakagami F, Kunugiza Y, Tomita T, Yoshikawa H, Rakugi H, Ogihara T, Morishita R. Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertens Res 2009; 32: 786-790.
35. Shimizu H, Nakagami H, Yasumasa N, Osako MK, Shimamura M, Miyake T, Nakagami F, Koriyama H, Rakugi H, Morishita R. Combination of thiazide diuretics and angiotensin receptor blockers attenuates osteoporosis in hypertensive rats. Immun Endocr Metab Agents Med Chem 2010; 10: 115-122.
36. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 2000; 100: 197-207. (Pubitemid 30064908)
37. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, Kondo H, Richards WG, Bannon TW, Noda M, Clement K, Vaisse C, Karsenty G. Leptin regulation of bone resorption by the sympathetic nervous system and cart. Nature 2005; 434: 514-520. (Pubitemid 40477060)
38. Hohmann EL, Elde RP, Rysavy JA, Einzig S, Gebhard RL. Innervation of periosteum and bone by sympathetic vasoactive intestinal peptide-containing nerve fibers. Science 1986; 232: 868-871. (Pubitemid 16117395)
39. Moore RE, Smith II CK, Bailey CS, Voelkel EF, Tashjian Jr AH. Characterization of betaadrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 1993; 23: 301-315.
40. Bowler WB, Gallagher JA, Bilbe G. G-protein coupled receptors in bone. Front Biosci 1998; 3: d769-d780.